Health is all we are concerned about.
As a national high-tech enterprise, Bioantibody focuses on providing comprehensive IVD solutions for customers. relying on professional R&D strength, reliable production quality and excellent sales capability, Bioantibody has always been committed to promoting the accurate diagnosis of human diseases with high-quality IVD solutions.
Bioantibody adheres to science and technology as the guide, continues to improve the level of independent research and development technology, and has been gradually established “3 + 4” development technologies and R&D platforms. The three major raw material development technologies include high-efficiency protein expression & purification technology, patented fusion screening technology, and phage display technology. and the four major product development platforms include immunoturbidimetric platform, chemiluminescence platform, immunochromatography platform and molecular POCT platform.
Based on the “3+4” technology platform, Bioantibody takes upstream raw materials as its core advantages, continuously expands downstream platforms, and successfully develops hot-selling reagent products for the in vitro diagnostic industry, such as SARS-CoV-2 antibody detection reagents, SARS-CoV-2 antigen Detection reagents, influenza A and B antigen detection reagents, monkeypox virus antibody detection reagents, monkeypox virus antigen detection reagents etc., covering cardiovascular disease, infectious disease, inflammatory index, gastric function, tumor index, hormone etc.
Based on own technology platform, Bioantibody is able to shorten productization cycle, raise technical barriers and improve excellent product performance. Bioantibody will respond quickly to the market, and show a promising trend of continuous growth.